Details for New Drug Application (NDA): 211246
✉ Email this page to a colleague
The generic ingredient in ESLICARBAZEPINE ACETATE is eslicarbazepine acetate. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the eslicarbazepine acetate profile page.
Summary for 211246
| Tradename: | ESLICARBAZEPINE ACETATE |
| Applicant: | Lupin Ltd |
| Ingredient: | eslicarbazepine acetate |
| Patents: | 0 |
Pharmacology for NDA: 211246
| Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 211246
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ESLICARBAZEPINE ACETATE | eslicarbazepine acetate | TABLET;ORAL | 211246 | ANDA | Lupin Pharmaceuticals, Inc. | 68180-290 | 68180-290-06 | 30 TABLET in 1 BOTTLE (68180-290-06) |
| ESLICARBAZEPINE ACETATE | eslicarbazepine acetate | TABLET;ORAL | 211246 | ANDA | Lupin Pharmaceuticals, Inc. | 68180-291 | 68180-291-06 | 30 TABLET in 1 BOTTLE (68180-291-06) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Mar 27, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 400MG | ||||
| Approval Date: | Mar 27, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG | ||||
| Approval Date: | Mar 27, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
